# FEB 1 6 2006

# 510(k) Summary - Chloride Electrode Gen. 2

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence

# Submitter name, address, contact

Roche Diagnostics Corporation   
9115 Hague Rd   
Indianapolis IN 46250   
(317) 521-3831

Contact person: Corina Harper

Date prepared: January 12, 2006

Chloride   
Electrode Gen. 2

Proprietary name: COBAS INTEGRA Chloride Electrode Gen. 2

Common name: Chloride Test System

Classification name: Ion-Specific Electrode Chloride

# Device description

The ISE module of the COBAS INTEGRA systems is intended for use for the quantitative determination of sodium, potassium, chloride in serum, plasma and urine, and lithium in serum and plasma, using ion-selective electrodes.

The ion-selective electrode is using undiluted (ISE Direct) or automatically diluted (ISE Indirect, ISE Urine) specimens.

This Chloride electrode is recommended to be used if a significant amount of the samples are plasma samples. Serum and urine samples may also be analyzed with this electrode.

# 510(k) Summary - Chloride Electrode Gen. 2, Continued

# Intended use

The ISE module of the COBAS INTEGRA systems is intended for use for the quantitative determination of sodium, potassium, chloride in serum, plasma and urine, and lithium in serum and plasma, using ion-selective electrodes.

This Chloride electrode is recommended to be used if a significant amount of the samples are plasma samples. Serum and urine samples may also be analyzed with this electrode.

# Predicate Device

We claim substantial equivalence to the currently marketed ISE Chloride Electrode cleared for use under K963627 on October 24, 1996.

Substantial equivalency - similarities

The table below indicates the similarities between the predicate device (K963627) and the modified Chloride Electrode Gen. 2.

<table><tr><td>Feature</td><td>Predicate Device - Chloride Electrode (approved via K963627)</td><td>Modified Chloride Electrode Gen. 2</td></tr><tr><td>General</td><td>ISE Direct:</td><td>The ISE module of the COBAS INTEGRA</td></tr><tr><td rowspan="2">Intended Use</td><td>The ISE module of the COBAS INTEGRA systems is intended for use for the quantitative determination of sodium, potassium, chloride and lithium concentrations in undiluted serum and plasma using ion-selective electrode. ISE Indirect: The ISE module of the COBAS INTEGRA systems is intended for use for the quantitative</td><td>systems is intended for use for the quantitative determination of sodium, potassium, chloride in serum, plasma and urine, and lithium in serum and plasma, using ion-selective electrodes. This Chloride electrode is recommended to be</td></tr><tr><td>determination of sodium, potassium, chloride concentrations in diluted serum and plasma using ion-selective electrode. ISE in Urine: The ISE module of the COBAS INTEGRA systems is intended for use for the quantitative determination of sodium, potassium, chloride</td><td>used if a significant amount of the samples are plasma samples. Serum and urine samples may also be analyzed with this electrode.</td></tr><tr><td>Sample type</td><td>concentrations in diluted urine using ion- selective electrode. Serum, plasma, urine</td><td>Same</td></tr></table>

# 510(k) Summary - Chloride Electrode Gen. 2, Continued

Substantial equivalency - similarities (continued)

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Predicate Device - ChlorideElectrode(approved via K963627)</td><td rowspan=1 colspan=1>Modified Chloride Electrode Gen. 2</td></tr><tr><td rowspan=1 colspan=3>Electrode Information</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>ISE solutions 1,2,3ISE Calibrator DirectISE Calibrator Indirect/Urine5 hours calibration interval (maincalibration), every sample (one-pointcalibration)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Qualitycontrol</td><td rowspan=1 colspan=1>Serum/Plasma: PreciNorm U,Precipath UUrine: Quantitative Urine Controls</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=3>Performance Characteristics</td></tr><tr><td rowspan=1 colspan=1>Expectedvalues foradults -mmol/L</td><td rowspan=1 colspan=1>ISE Direct Serum/Plasma 101-110ISE Indirect Serum/plasma 98-107ISE Urine 110-250</td><td rowspan=1 colspan=1>Same</td></tr></table>

# 510(k) Summary - Chloride Electrode Gen. 2, Continued

Substantial equivalency - similarities (continued)   

<table><tr><td>Feature</td><td>Predicate Device - Chloride Electrode (approved via K963627)</td><td>Modified Chloride Electrode Gen. 2</td></tr><tr><td>Endogenous Interferences</td><td>ISE Direct and Indirect (serum/plasma): Hemolysis - no significant interferences up to a hemoglobin level of 10 g/L</td><td>Same</td></tr><tr><td rowspan="4">Exogenous Interference</td><td>Lipemia - no significant interferences Icterus - no significant interferences</td><td></td></tr><tr><td>ISE Direct (serum/plasma) Probenecid causes artificially high</td><td>ISE Direct (serum/plasma) Ca-Dobesilate, Phenylbutazone,</td></tr><tr><td>chloride concentrations.</td><td>Acetylsalicylic acid and Ibuprofen causes artificially high chloride concentrations.</td></tr><tr><td>Salicylic acid concentration of 1.2 mmol/L increase chloride concentration by aprox. 10%</td><td>Same</td></tr><tr><td rowspan="2">ISE Urine Drug panel tested caused no significant interferences up to the indicated concentrations in the label.</td><td>ISE Indirect (serum/plasma) Acetylsalicylic acid causes artificial</td><td>ISE Indirect(serum/plasma) Acetylsalicylic acid and Ibuprofen</td></tr><tr><td>high Chloride concentrations.</td><td>causes artificial high chloride concentrations. ISE Urine:</td></tr></table>

# 510(k) Summary - Chloride Electrode Gen. 2, Continued

Substantial equivalency - differences

The table below indicates the differences between the predicate device (K963627) and the modified Chloride Electrode Gen. 2.

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Predicate Device - ChlorideElectrode(approved via K963627)</td><td rowspan=1 colspan=1>Modified Chloride Electrode Gen. 2</td></tr><tr><td rowspan=1 colspan=1>OnboardStability</td><td rowspan=1 colspan=1>3 months(serum samples only, reduced whenplasma sample are used)</td><td rowspan=1 colspan=1>2 months or 6000 samples(when majority of plasma samples areused)</td></tr><tr><td rowspan=1 colspan=3>Performance Characteristics</td></tr><tr><td rowspan=1 colspan=1>PrecisionISE DirectmodeCV%</td><td rowspan=1 colspan=1>Within run CV% (n=20):0.69% @ 86 mmol/L0.46% @ 99mmol/LBetween run CV% (n=20):1.3% @ 86 mmol/L0.92%@ 99 mmol/L</td><td rowspan=1 colspan=1>Within run CV% (n=21):Serum:0.19% @ 92.9 mmol/L0.19% @ 127.2 mmol/LPlasma (low n=20, high n=21):0.36% @ 89.2 mmol/L0.15% @ 125 mmol/LBetween day CV% (n=21):Serum:0.9% @ 94.3 mmol/L1.1% @ 126.5 mmol/LPlasma:1.0% @ 91.6 mmol/L1.2% @ 126.0 mmol/LTotal CV%Serum:0.9%@ 94.4 mmol/L1.1% @ 126.4 mmol/LPlasma:1.0% @ 91.8 mmol/L1.4% @ 125.8 mmol/L</td></tr></table>

# 510(k) Summary - Chloride Electrode Gen. 2, Continued

Substantial equivalency $\cdot$ differences (continued)   

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Predicate Device - ChlorideElectrode(approved via K963627)</td><td rowspan=1 colspan=1>Modified Chloride Electrode Gen. 2</td></tr><tr><td rowspan=1 colspan=3>Performance Characteristics</td></tr><tr><td rowspan=1 colspan=1>ISE IndirectmodeCV%</td><td rowspan=1 colspan=1>Within run CV% (n=20):0.77% @ 87 mmol/L0.72% @ 101 mmol/LBetween run CV% (n=20):1.5% @ 87 mmol/L1.2%@ 101 mmol/L</td><td rowspan=1 colspan=1>Within run CV%(n=21):Serum:0.65% @ 90.3 mmol/L0.25% @ 124.1 mmol/LPlasma:0.29% @ 86.4 mmol/L0.23% @ 121.9 mmol/LBetween day CV%(n=21):Serum:1.0% @ 92.0 mmol/L0.9% @ 122.8 mmol/LPlasma:1.1% @ 88.7 mmol/L1.0% @ 121.6 mmol/LTotal CV%:Serum:1.0%@ 92.1mmol/L1.0% @ 122.8 mmol/LPlasma:1.1% @ 88.8 mmol/L1.0% @ 121.6 mmol/L</td></tr></table>

# 510(k) Summary - Chloride Electrode Gen. 2, Continued

Substantial equivalency - differences (continued)   

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Predicate Device - ChlorideElectrode(approved via K963627)</td><td rowspan=1 colspan=1>Modified Chloride Electrode Gen. 2</td></tr><tr><td rowspan=1 colspan=1>ISE UrinemodeCV%</td><td rowspan=1 colspan=1>Within run CV% (n=20):0.97% @ 53 mmol/L1.2%@ 267 mmol/LBetween run CV% (n=20):2.8% @ 53 mmol/L2.2%@ 267 mmol/L</td><td rowspan=1 colspan=1>Within run CV% (low n=21, highn=20):0.5% @ 61.4 mmol/L0.5% @ 194.4 mmol/LBetween day (n=21):2.3% @ 64.9 mmol/L4.3% @ 186.4 mmol/LTotal:2.8%@ 65.1mmol/L4.4% @ 186.5 mmol/L</td></tr><tr><td rowspan=1 colspan=1>Linearity(mmol/L)</td><td rowspan=1 colspan=1>ISE Direct - Serum/plasma: 20-250ISE Indirect - Serum/plasma: 20-250ISE Urine: 20-350</td><td rowspan=1 colspan=1>ISE Direct - Serum/Plasma: 60-140ISE Indirect - Serum/Plasma: 60-140ISE Urine: 20-250</td></tr><tr><td rowspan=1 colspan=1>Sensitivity forelectrode:slope</td><td rowspan=1 colspan=1>-42 to -56 mV/dec</td><td rowspan=1 colspan=1>ISE Direct: -35 to -56 mV/decISE Indirect: -38 to -56 mV/dec</td></tr></table>

# FEB 1 6 2006

Ms. Corina Harper   
Regulatory Affairs Consultant   
Roche Diagnostics   
9115 Hague Road   
Indianapolis, IN 46256

Re: k060108 Trade/Device Name: Chloride Electrode Gen. 2 Regulation Number: 21 CFRÂ§ 862.1170 Regulation Name: Chloride test system Regulatory Class: Class II Product Code: CGZ Dated: January 12, 2006 Received: January 27, 2006

Dear Ms. Harper

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/4b69c4436a505af0d88796a2148734f55f1b2675f5b236b294ce7f9d23f81aed.jpg)

Alberto Gutierrez, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known):

Chloride Electrode Gen. 2: Chloride Electrode Gen. 2

Indications For Use:

The ISE module of the COBAS INTEGRA systems is intended for use for the quantitative determination of sodium, potassium, chloride in serum, plasma and urine, and lithium in serum and plasma, using ion-selective electrodes.

This Chloride electrode is recommended to be used if a significant amount of the samples are plasma samples. Serum and urine samples may also be analyzed with this electrode.

Chloride measurements are used in diagnosis and treatment of electrolyte and metabolic disorders.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Canf Beem

Cffice of In Vitro Diagnostic Device ivoluation and Safety

K060108